Periscope: Ex-Bax­al­ta ex­ec David Meek takes Paris-based helm for Ipsen

David Meek is head­ed to Paris. Ipsen, which had seen its top ranks roiled ear­li­er this year, named the on­col­o­gy chief of the short-lived Bax­al­ta as its new CEO. Meek had helped steer Bax­al­ta in­to a string of new can­cer drug deals, which were hap­pen­ing even af­ter Shire an­nounced that it had com­plet­ed a deal to ac­quire the com­pa­ny.  “He will fo­cus on strat­e­gy, on the con­tin­u­a­tion of the Group trans­for­ma­tion plan and on op­er­a­tions,” an Ipsen spokesper­son tells End­points, con­firm­ing that Meek will be re­lo­cat­ing to the com­pa­ny’s HQ in Boulogne Bil­lan­court. “He will be tasked with en­sur­ing the de­vel­op­ment of the spe­cial­ty care ac­tiv­i­ties as well as pri­ma­ry care, and with pur­su­ing the group in­ter­na­tion­al­iza­tion in the US and Chi­na.” Meek’s deals in­volved hun­dreds of mil­lions of up­front dol­lars for pacts with Sym­phogen, Pre­ci­sion Bio­Sciences and oth­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER